Ascendis signs license agreement with Japanese pharma company
Danish biotech company Ascendis Pharma has announced that it has entered into a partnership with Japanese Teijin Limited, giving the latter the right to further develop and commercialize Ascendis Pharma’s three pipeline hopes within rare endocrinological diseases in the Japanese market.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Ascendis CFO sells shares worth DKK millions
For subscribers